Simultaneously, Rg5 demonstrates the capacity to activate the LKB1/AMPK/mTOR signaling pathway, instigating energy metabolism and consequently hindering the progression of NAFLD. This evidence concerns the gene MTOR and metabolic dysfunction-associated steatotic liver disease.